Maider Pretel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maider Pretel has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Leyre Aguado
Dermatology Department, University Clinic of Navarra, Pamplona, Spain
16 shared publications - Agustín España
Department of Dermatology, University Clinic of Navarra, Pamplona, Spain
6 shared publications - Miguel Angel Idoate
Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain
5 shared publications M. Marquina
Department of Dermatology, University Clinic of Navarra, Pamplona, Spain
4 shared publications- Pedro Redondo
Department of Dermatology University Clinic of Navarra Madrid Spain
4 shared publications - Isabel Bernad
Department of Dermatology, Miguel Servet University Hospital, IIS Aragón, Zaragoza, Spain
3 shared publications
Latest Publications
- Open Access
- 13 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5727
Real-World Clinical Practice Evaluation of Tralokinumab in Atopic Dermatitis: A 52-Week Multi-Center Retrospective Study in the Basque Country
Background: Tralokinumab is an anti-IL-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD). While pivotal trials have demonstrated its efficacy, real-world data remain limited. Methods: We conducted a retrospective, multi-center study in the Basque Country including 109 adults with moderate-to-severe AD treated with tralokinumab. Clinical outcomes (EASI, IGA, BSA, DLQI, and NRS-pruritus/sleep) were assessed at baseline, weeks 16, 24, and 52. Results: EASI-75/90/100 responses were 66%/44%/16% at week 16 and increased to 83%/70%/34% at week 52. Pruritus NRS decreased from 7.1 to 3.1 and DLQI from 17.8 to 9.0. Adverse events were uncommon, with only three cases of conjunctivitis (two discontinued). Conclusions: Our findings support tralokinumab as a safe and effective long-term therapy for AD in routine practice. Results were consistent with, or superior to, pivotal and other RWE studies.
- 13 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5727
Open AccessReal-World Clinical Practice Evaluation of Tralokinumab in Atopic Dermatitis: A 52-Week Multi-Center Retrospective Study in the Basque Country
Background: Tralokinumab is an anti-IL-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD). While pivotal trials have demonstrated its efficacy, real-world data remain limited. Methods: We conducted a retrospective, multi-center study in the Basque Country including 109 adults with moderate-to-severe AD treated with tralokinumab. Clinical outcomes (EASI, IGA, BSA, DLQI, and NRS-pruritus/sleep) were assessed at baseline, weeks 16, 24, and 52. Results: EASI-75/90/100 responses were 66%/44%/16% at week 16 and increased to 83%/70%/34% at week 52. Pruritus NRS decreased from 7.1 to 3.1 and DLQI from 17.8 to 9.0. Adverse events were uncommon, with only three cases of conjunctivitis (two discontinued). Conclusions: Our findings support tralokinumab as a safe and effective long-term therapy for AD in routine practice. Results were consistent with, or superior to, pivotal and other RWE studies.
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , e73-e74
Reply to: “Topical rapamycin combined with pulsed dye laser (PDL) in the treatment of capillary vascular malformations—Anatomical differences in response to PDL are relevant to interpretation of study results”
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , e73-e74
Reply to: “Topical rapamycin combined with pulsed dye laser (PDL) in the treatment of capillary vascular malformations—Anatomical differences in response to PDL are relevant to interpretation of study results”
- 15 April 2015
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 17 (6) , 304-306
Nd:YAG Q-switched laser for the treatment of a hemicorporal epidermal nevus: A safe and effective option
Epidermal nevi are benign proliferations of the epidermis for which different treatments have been used with disappointing results due to their recurrences and anesthetic scars. Topical therapies have generally been ineffective and surgical treatment provides more definitive results, but with high risk of scarring. In recent years, multiple laser modalities have been described for the treatment of these lesions. In the literature, there are no reported cases of treatment of these lesions with Neodymium-doped Yttrium aluminum garnet (Nd:YAG) laser. We present the case of a 3-year-old patient with a hemicorporal epidermal nevus treated with Nd:YAG laser at an early stage with good results.
- 15 April 2015
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 17 (6) , 304-306
Nd:YAG Q-switched laser for the treatment of a hemicorporal epidermal nevus: A safe and effective option
Epidermal nevi are benign proliferations of the epidermis for which different treatments have been used with disappointing results due to their recurrences and anesthetic scars. Topical therapies have generally been ineffective and surgical treatment provides more definitive results, but with high risk of scarring. In recent years, multiple laser modalities have been described for the treatment of these lesions. In the literature, there are no reported cases of treatment of these lesions with Neodymium-doped Yttrium aluminum garnet (Nd:YAG) laser. We present the case of a 3-year-old patient with a hemicorporal epidermal nevus treated with Nd:YAG laser at an early stage with good results.
- 1 January 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 72 (1) , S73-S75
Dermoscopic “setting sun” pattern of juvenile xanthogranuloma
- 1 January 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 72 (1) , S73-S75
Dermoscopic “setting sun” pattern of juvenile xanthogranuloma
- 1 January 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 72 (1) , 151-158.e1
Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: Phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial
- 1 January 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 72 (1) , 151-158.e1
Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: Phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial
- 1 October 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (4) , e121-e122
Reddish plaque on the arm of a 53-year-old woman
- 1 October 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (4) , e121-e122
Reddish plaque on the arm of a 53-year-old woman
- 25 September 2014
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 16 (6) , 314-316
Accelerated photoaging induced by voriconazole treated with Q-switched Nd:YAG laser: Case report and review of the literature
Voriconazole is an antifungal agent mainly used against aspergillosis. Given its wide spectrum of action and limited adverse effects, it has replaced amphotericin B as the drug of choice in the prophylactic treatment of immunocompromised patients. Several adverse effects are caused by this drug with dermatological reactions accounting for 6% of the total. Such reactions include cheilitis, erythema, erosions, discoid lupus erythematosus, erythema multiforme, photosensitivity reactions, pseudoporphyria, accelerated photoaging and skin cancer. There are few reports on the accelerated photoaging caused by voriconazole and its effective treatment. Here we present the case of a 6-year-old child with a history of chronic granulomatous disease under prolonged treatment with voriconazole, who developed accelerated photoaging lesions secondary to the chronic use of this antifungal agent. Treatment was initiated using Q-switched Nd:YAG laser with good results.
- 25 September 2014
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 16 (6) , 314-316
Accelerated photoaging induced by voriconazole treated with Q-switched Nd:YAG laser: Case report and review of the literature
Voriconazole is an antifungal agent mainly used against aspergillosis. Given its wide spectrum of action and limited adverse effects, it has replaced amphotericin B as the drug of choice in the prophylactic treatment of immunocompromised patients. Several adverse effects are caused by this drug with dermatological reactions accounting for 6% of the total. Such reactions include cheilitis, erythema, erosions, discoid lupus erythematosus, erythema multiforme, photosensitivity reactions, pseudoporphyria, accelerated photoaging and skin cancer. There are few reports on the accelerated photoaging caused by voriconazole and its effective treatment. Here we present the case of a 6-year-old child with a history of chronic granulomatous disease under prolonged treatment with voriconazole, who developed accelerated photoaging lesions secondary to the chronic use of this antifungal agent. Treatment was initiated using Q-switched Nd:YAG laser with good results.
- Open Access
- 1 September 2014
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 105 (7) , 655-662
Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
- 1 September 2014
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 105 (7) , 655-662
Open AccessAdverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
- 1 September 2014
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 105 (7) , 655-662
Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)
- 1 September 2014
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 105 (7) , 655-662
Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)
- Open Access
- 1 June 2014
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 150 (6) , 664-666
Acute Generalized Exanthematous Pustulosis Induced by Sorafenib
Case Report from JAMA Dermatology — Acute Generalized Exanthematous Pustulosis Induced by Sorafenib
- 1 June 2014
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 150 (6) , 664-666
Open AccessAcute Generalized Exanthematous Pustulosis Induced by Sorafenib
Case Report from JAMA Dermatology — Acute Generalized Exanthematous Pustulosis Induced by Sorafenib